New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 3, 2014
08:16 EDTTEVA, ALXATeva launches ADASUVE in U.S.
Teva Pharmaceutical (TEVA) announced the commercial launch of ADASUVE inhalation powder 10 mg, the first and only orally inhaled medicine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. ADASUVE is administered through Alexza Pharmaceuticals' (ALXA) innovative proprietary Staccato single-use, hand held drug delivery technology system. This new drug-device combination product provides rapid systemic delivery by inhalation of a thermally-generated aerosol of loxapine, a first generation antipsychotic, to the lung. Administration of ADASUVE results in rapid absorption of loxapine, with a maximum plasma concentration achieved in approximately 2 minutes. Efficacy was demonstrated in two clinical trials in acute agitation: one in schizophrenia and one in bipolar I disorder. Patients receiving ADASUVE experienced a statistically significant reduction in agitation at two hours, with an effect seen as early as ten minutes post-dose.
News For TEVA;ALXA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 29, 2014
07:19 EDTTEVAUBS to hold a field trip
Subscribe for More Information
05:26 EDTTEVAProtalix appoints Moshe Manor as CEO
Subscribe for More Information
September 18, 2014
09:09 EDTALXAAlexza Pharmaceuticals updates Adasuve inhalation powder marketing in Europe
Subscribe for More Information
September 17, 2014
11:01 EDTTEVAActavis drops after NY AG seeks to block Alzheimer drug switch
Subscribe for More Information
08:05 EDTTEVAEagle Pharm says Teva requests motion to dismiss Bendamustine lawsuit
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use